Vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus
View Patent ↗The present invention is directed to novel immunogenic compositions that protect swine from disease caused by porcine epidemic diarrhea virus (PEDV). The present invention is also directed to novel immunogenic compositions that protect swine from disease caused by porcine deltacoronavirus (PDCoV), alone or as combination vaccine to protect against PEDV. The compositions of the invention provide killed viruses whose effectiveness is enhanced by the selection of preferred adjuvants. Novel culture methods are also employed to increase reproducible yield of cultured viruses. Live vaccines are also provided from the Calaf14 PEDV isolate.
1. A method of producing a neutralizing antibody response against PEDV in a subject swine comprising administering to the subject an immunogenic composition comprising inactivated porcine epidemic diarrhea virus (PEDV), adjuvanted in a stabilized oil-in-water emulsion of lecithin and mineral oil also containing aluminum hydroxide, in an amount and duration effective to produce the neutralizing antibody response.
2. The method of claim 1 , wherein vaccination provides protection against challenge by a PEDV virus that has 90%, 95%, 96%, 97%, 98% or 99% identity to the S-protein (SEQ ID NO:4) of PEDV strain Calaf14.
3. The method of claim 2 wherein said identity is at least 98%, preferably 99%.
4. The method of claim 1 wherein the inactivated PEDV is strain USA/Colorado/2013, whose full length encoding nucleotide sequence is provided by SEQ ID NO: 7.
5. The method of claim 1 wherein the final concentrations of lecithin and mineral oil are 0.5% and 4.5% respectively.
6. A method of producing a neutralizing antibody response against porcine deltacoronavirus (PDCoV) in a subject swine, comprising administering to the subject the immunogenic composition comprising both inactivated porcine epidemic diarrhea virus (PEDV) and inactivated porcine deltacoronavirus (PDCoV), adjuvanted as an oil-in-water emulsion, wherein the adjuvant components include Amphigen® and aluminum hydroxide, in an amount and duration effective to produce the neutralizing antibody response against PDCoV.
7. The method of claim 6 wherein the inactivated PDCoV is selected from the group consisting of USA/Michigan/8977/2014, whose full length encoding nucleotide sequence is provided as SEQ ID NO:12, and strain USA/Indiana/2014/8501010, whose full length encoding nucleotide sequence is SEQ ID NO: 11.
8. The method of claim 6 wherein the final concentrations of lecithin and mineral oil are 0.5% and 4.5% respectively.